Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

9:28 AM ET 8-K
Capital Raise Healthstream Inc HSTM

Healthstream Capital Raise of $40M

HealthStream completed a $40 million private placement of 1,355,932 newly issued shares of common stock to WJRJJ Ventures, LLC at $29.50 per share. Simultaneously, CEO Robert A. Frist, Jr. sold an additional 144,068 shares to the same investor for $4.25 million. The company intends to use the proceeds for general corporate purposes, including potential acquisitions and strategic initiatives.

Value
$40M
Counterparty
WJRJJ Ventures, LLC
9:26 AM ET 8-K
Capital Raise Dream Finders Homes, Inc. DFH

Dream Finders Homes Capital Raise of $225M

Dream Finders Homes, Inc. entered into subscription agreements with institutional investors to sell 225,000 shares of newly-created Series B Convertible Preferred Stock for $225 million. The proceeds were used to redeem existing Series A Preferred Stock, with a second closing of $450 million contingent upon the completion of the company's pending merger with Beazer Homes USA, Inc.

Value
$225M
Counterparty
institutional investors
9:21 AM ET 8-K
Loan & Debt Federal Home Loan Bank of Pittsburgh

Federal Home Loan Bank of Pittsburgh $2.17B Debt Financing

Federal Home Loan Bank of Pittsburgh reported the commitment to issue several series of consolidated obligation bonds and discount notes between September 9 and September 11, 2026. The issuances include a mix of fixed-rate and variable-rate instruments with maturities ranging from late 2026 to 2046, totaling approximately $2.17 billion in par value. These obligations are the joint and several liabilities of the eleven Federal Home Loan Banks and are used to fund the bank's operations.

Value
$2.17B
Term
through Sept 2046
9:16 AM ET 8-K
Leadership Change Federal Home Loan Bank of Chicago

Federal Home Loan Bank of Chicago Leadership Change

James H. Hegenbarth was declared director-elect to the Board of Directors of the Federal Home Loan Bank of Chicago for a four-year term beginning January 1, 2027. Mr. Hegenbarth, who currently serves as President and Director of Bank CMG, was appointed without a formal election as the number of nominees matched the number of open directorships for the state of Wisconsin.

Counterparty
James H. Hegenbarth
Term
4 years
9:12 AM ET 8-K
Other 8-K Filing WhiteHorse Finance, Inc. WHF

WhiteHorse Finance Other 8-K Filing

WhiteHorse Finance, Inc. has formed a special committee of independent directors to explore strategic alternatives, which may include a potential sale of the company or other corporate transactions. The committee has not established a specific timetable for the review and there is no guarantee that the process will result in a transaction.

9:10 AM ET 8-K
Reverse Stock Split Jaguar Health, Inc. JAGX

Jaguar Health Reverse Stock Split

Jaguar Health is implementing a 1-for-15 reverse stock split of its common stock, effective September 17, 2026. The move is intended to bring the company back into compliance with Nasdaq's minimum bid price listing standards. Every 15 shares of existing common stock will be consolidated into one share, with no change to the par value or total authorized shares.

9:08 AM ET 8-K
Leadership Change Claritev Corp CTEV

Claritev Leadership Change

Claritev Corporation appointed Ben Letham to its Board of Directors as a Class I director and a member of the Risk Committee, effective September 14, 2026. Mr. Letham, currently a research scientist at Meta and an expert in artificial intelligence, fills the vacancy created by the passing of former director John Prince. He will receive compensation in accordance with the company's standard non-employee director policy.

Counterparty
Ben Letham
9:07 AM ET 8-K
M&A Deal Jazz Pharmaceuticals plc JAZZ

Jazz Pharmaceuticals Signs $820M M&A Deal with Actio Biosciences, Inc.

Jazz Pharmaceuticals completed its acquisition of Actio Biosciences for $820 million upfront, making Actio a wholly-owned subsidiary. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, to Jazz's rare disease and epilepsy pipeline. As part of the transaction, Actio spun out its non-ABS-1230 programs into a new private entity in which Jazz retains a minority stake.

Value
$820M
Counterparty
Actio Biosciences, Inc.
9:06 AM ET 8-K
Investor Presentation Bandwidth Inc. BAND

Bandwidth Investor Presentation

Bandwidth Inc. filed a formal investor presentation deck to be used at various investor conferences during the third quarter of 2026. The presentation provides a strategic overview of the company's product offerings, platform value proposition, and anticipated market growth.

9:05 AM ET 8-K
Dividend First Bancorp FBNC

First Bancorp Dividend

First Bancorp's board of directors declared a quarterly cash dividend of $0.24 per share on its common stock. The dividend is payable on October 23, 2026, to shareholders of record as of September 30, 2026.

9:03 AM ET 8-K
Executive Compensation Tredegar Corp TG

Tredegar Executive Compensation

Tredegar Corporation has appointed Cindy Yao as Vice President, Chief Financial Officer and Treasurer, effective September 21, 2026. Her compensation package includes an annual base salary of $450,000, a target bonus of 60% of base salary, and long-term incentive awards targeted at 80% of base salary consisting of restricted stock and cash.

Counterparty
Cindy Yao
9:01 AM ET 8-K
Other 8-K Filing Innventure, Inc. INV

Innventure Other 8-K Filing

Senior management and directors of Innventure, Inc. voluntarily forfeited 435,168 earnout shares previously issued for the achievement of 'Milestone One' under a business combination agreement. The forfeiture follows a change in status of a $15 million purchase order from DarkNX Ltd., which was the basis for the milestone, after the intended deployment site became unavailable.

9:01 AM ET 8-K
Other 8-K Filing Origin Bancorp, Inc. OBK

Origin Bancorp Other 8-K Filing

Origin Bancorp, Inc. (OBK) is voluntarily withdrawing its common stock listing from the New York Stock Exchange (NYSE) to transfer to the newly established Texas Stock Exchange (TXSE). The company expects to cease trading on the NYSE at the close of business on October 12, 2026, and commence trading on the TXSE as a founding member on October 13, 2026.

Counterparty
Texas Stock Exchange
9:01 AM ET 8-K
M&A Deal 5E Advanced Materials, Inc. FEAM

5E Advanced Materials M&A Deal with Searles Valley Minerals Inc.

5E Advanced Materials has entered into a definitive asset purchase agreement to acquire the operating assets of Searles Valley Minerals through a Section 363 bankruptcy sale process. The acquisition includes critical mineral production facilities, 9,000 acres of brine resources, and integrated infrastructure in California, transforming 5E from a pre-revenue developer into an active producer of borates and boric acid. Consideration for the deal consists of $3.4 million in cash, 8.3 million shares of common stock, and a $6.2 million senior unsecured promissory note.

Counterparty
Searles Valley Minerals Inc.
9:00 AM ET 8-K
Leadership Change Cabot Corp CBT

Cabot Leadership Change

Cabot Corporation appointed Steven J. Delahunt as interim Chief Financial Officer, effective October 1, 2026. He replaces Erica McLaughlin, who is transitioning to the role of President and CEO, while the company continues its search for a permanent CFO. Delahunt will receive a monthly cash stipend of $35,000 in addition to his existing compensation during the interim period.

8:58 AM ET 8-K
Capital Raise GT Biopharma, Inc. GTBP

GT Biopharma Capital Raise of $7.45M

GT Biopharma entered into a securities purchase agreement for a private placement of up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and associated warrants for an initial purchase price of $7.45 million. The agreement includes 'Greenshoe Rights' allowing purchasers to acquire additional preferred stock with a stated value of up to $33.33 million for an additional $30 million. The preferred stock is convertible into common stock at an initial conversion price of $6.10 per share.

Value
$7.45M
8:55 AM ET 8-K
Other 8-K Filing Santander Holdings USA, Inc. SNUS-PH

Santander Holdings USA Other 8-K Filing

Santander Holdings USA, Inc. announced it will redeem all 135,000 outstanding shares of its Series I Preferred Stock and the corresponding 5,400,000 depositary shares on October 15, 2026. The redemption will be conducted at a price of $25.00 per depositary share, totaling $135 million in cash outflows to retire the equity class.

8:55 AM ET 8-K
Clinical Trial Data Pulse Biosciences, Inc. PLSE

Pulse Biosciences Clinical Trial Data

Pulse Biosciences announced the completion of patient enrollment in its PRECISE-BTN clinical study, which evaluated the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study was expanded from 50 to 100 patients across three U.S. sites, and the first patient has already completed the final 12-month follow-up visit. Preliminary data is expected to be presented at an upcoming medical conference.

8:52 AM ET 8-K
Loan & Debt PBF Holding Co LLC PBF

PBF Holding Co $500M Debt Financing

PBF Holding Company LLC priced a private offering of $500 million in 0% senior unsecured exchangeable notes due 2032. The notes are senior unsecured obligations and include an additional $50 million overallotment option for initial purchasers. The notes do not bear regular interest and are exchangeable into cash, PBF Energy common stock, or a combination thereof at an initial exchange price of approximately $96.80 per share.

Value
$500M
Term
through Jan 2032
8:52 AM ET 8-K
Executive Compensation Catalyst Bancorp, Inc. CLST

Catalyst Bancorp Executive Compensation

Catalyst Bank entered into new three-year employment agreements with its COO Amanda Quebedeaux and CFO Jacques Bourque. The agreements establish base salaries of $162,500 and $117,500 respectively, and include provisions for 12 months of base salary as severance in the event of involuntary termination or a change in control.

Counterparty
Amanda Quebedeaux and Jacques Bourque
Term
3 years
8:46 AM ET 8-K
Investor Presentation Astrana Health, Inc. ASTH

Astrana Health Investor Presentation

Astrana Health, Inc. filed an updated corporate investor presentation for September 2026 to be used in upcoming conferences and meetings. The presentation covers the company's business strategy, expansion plans, and financial targets, including its use of artificial intelligence capabilities.

8:45 AM ET 8-K
Other 8-K Filing Omniq Corp. OMQS

Omniq Other 8-K Filing

OMNIQ Corp. announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 12,633,155 B1 for its AI-based vehicle occupancy detection system used in HOV lane enforcement. The technology uses deep-learning and multiband line-scan imagery to automatically count vehicle occupants at highway speeds, addressing a total addressable U.S. market estimated at $218 million.

Counterparty
U.S. Patent and Trademark Office
8:45 AM ET 8-K
Clinical Trial Data Summit Therapeutics Inc. SMMT

Summit Therapeutics Clinical Trial Data

Summit Therapeutics announced updated overall survival (OS) results from its global Phase III HARMONi trial of ivonescimab in patients with EGFR-mutated non-small cell lung cancer. The updated June 2026 analysis showed a favorable OS hazard ratio of 0.76 in the global population, demonstrating consistent efficacy across both Western and Asian patient subgroups. No new safety signals were observed, reinforcing the potential of ivonescimab as a treatment option following progression on EGFR-targeted therapy.

Counterparty
Akeso Inc.
8:34 AM ET 8-K
Loan & Debt Scotts Miracle-Gro Co SMG

Scotts Miracle-Gro $250M Debt Financing with JPMorgan Chase Bank, N.A.

Scotts Miracle-Gro redeemed $250 million of its 5.250% Senior Notes due 2026 and renewed its $750 million accounts receivable facility with JPMorgan Chase Bank through August 2027. The company also initiated its $500 million share repurchase program with $25 million in buybacks executed in August and reaffirmed its full-year fiscal 2026 guidance.

Value
$250M
Counterparty
JPMorgan Chase Bank, N.A.
Term
through Aug 2027
8:32 AM ET 8-K
Other 8-K Filing Biomarin Pharmaceutical Inc BMRN

Biomarin Pharmaceutical Other 8-K Filing

BioMarin Pharmaceutical Inc. announced its decision to discontinue the clinical development of VOXZOGO for children with Noonan syndrome. The company cited study feasibility and the current treatment landscape as reasons for the move, noting the decision was not related to safety or efficacy.

8:31 AM ET 8-K
Investor Presentation Evommune, Inc. EVMN

Evommune Investor Presentation

Evommune, Inc. has filed an updated corporate presentation as an exhibit to its 8-K, providing a strategic overview of its clinical-stage portfolio including EVO756, EVO301, and EVO646. The presentation outlines the company's focus on chronic inflammatory diseases and highlights its leadership team's track record of approximately 30 approved NDAs and BLAs.

8:31 AM ET 8-K
Regulatory Approval Scholar Rock Holding Corp SRRK

Scholar Rock Holding Regulatory Approval

Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.

8:22 AM ET 8-K
Leadership Change USA Today Co., Inc. TDAY

USA Today Co Leadership Change

USA TODAY Co., Inc. has appointed Timothy Allen, the current CEO of Babbel, to its Board of Directors, effective September 15, 2026. Mr. Allen will also serve on the Audit and Transformation Committees and will receive standard pro-rated compensation for non-employee directors. The appointment increases the board size from eight to nine members.

Counterparty
Timothy Allen
8:20 AM ET 8-K
Stock Buyback AGNT, Inc. AGNT

AGNT Announces $32M Stock Buyback

AGNT, Inc. completed the repurchase of 8,693,290 shares of its common stock from the Gratitude 2022 Trust for approximately $32 million. The transaction was executed at a 10% discount to the 5-day volume-weighted average price to accelerate the company's capital return program and assist the trust with tax and estate administration.

Value
$32M
Counterparty
Gratitude 2022 Trust
8:18 AM ET 8-K
Executive Compensation Aethlon Medical Inc AEMD

Aethlon Medical Executive Compensation

Aethlon Medical amended the employment agreements for CEO/CFO James B. Frakes and CMO Steven P. LaRosa to modify severance payment terms. In the event of a change in control followed by a qualifying termination, severance and healthcare continuation payments will now be paid as a single lump sum rather than installments. The amendments do not change the total amount of compensation or the conditions required to trigger the benefits.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.